Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review

被引:7
作者
Konstantelos, N. [1 ]
Rzepka, A. M. [1 ]
Burden, A. M. [1 ,2 ]
Cheung, A. M. [3 ,4 ]
Kim, S. [1 ,5 ]
Grootendorst, P. [1 ,6 ]
Cadarette, S. M. [1 ,3 ,6 ,7 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
[2] Swiss Fed Inst Technol, Zurich, Switzerland
[3] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[4] Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON, Canada
[5] Womens Coll Hosp, Toronto, ON, Canada
[6] WHO Collaborating Ctr Governance Accountabil & Tr, Toronto, ON, Canada
[7] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA
基金
加拿大健康研究院;
关键词
Drug Safety; Research methodology; Osteoporotic fractures; Osteoporosis; Pharmacoepidemiology; BISPHOSPHONATE USE; IDENTIFICATION; CONSEQUENCES; VALIDATION; MANAGEMENT; DIAGNOSIS;
D O I
10.1007/s00198-022-06395-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A Summary Healthcare administrative (claims) data are commonly utilized to estimate drug effects. We identified considerable heterogeneity in fracture outcome definitions in a scoping review of 57 studies that estimated osteoporosis drug effects on fracture risk. Better understanding of the impact of different fracture definitions on study results is needed. Purpose Healthcare administrative (claims) data are frequently used to estimate the real-world effects of drugs. Fracture incidence is a common outcome of osteoporosis drug studies. We aimed to describe how fractures are defined in studies that use claims data. Methods We searched MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), and gray literature for studies published in English between 2000 and 2020 that estimated fracture effectiveness (hip, humerus, radius/ulna, vertebra) or safety (atypical fracture of the femur, AFF) of osteoporosis drugs using claims data in Canada and the USA. Literature searches, screening and data abstraction were completed independently by two reviewers. Results We identified 57 eligible studies (52 effectiveness, 3 safety, 2 both). Hip fracture was the most common fracture site studied (93%), followed by humerus (66%), radius/ulna (59%), vertebra (61%), and AFF (9%). Half (n = 29) of the studies did not indicate specific data sources, codes, or cite a validation paper. Of the papers with sufficient detail, heterogeneity in fracture definitions was common. The most common definition within each fracture site was used by less than half of the studies that examined effectiveness (12 definitions in 29 hip fracture papers, 8 definitions in 17 humerus papers, 8 definitions in 13 radius/ulna papers, 9 definitions in 15 vertebra papers), and 3 definitions among 4 AFF papers. Conclusion There is ambiguity and heterogeneity in fracture outcome definitions in studies that leverage claims data. Better transparency in outcome reporting is needed. Future exploration of how fracture definitions impact study results is warranted.
引用
收藏
页码:1837 / 1844
页数:8
相关论文
共 41 条
[1]  
[Anonymous], 2019, DEV APPR PROC DRUGS
[2]  
[Anonymous], PUBLIC HLTH AGENCY C
[3]  
[Anonymous], OSTEOPOROSIS CANADA
[4]  
[Anonymous], US FOOD DRUG ADM 202
[5]  
[Anonymous], American Society for Bone and Mineral Research (ASBMR)
[6]  
[Anonymous], Canadian Agency for Drugs and Technology in Health- Common Drug Review
[7]  
[Anonymous], 2004, BONE HLTH OSTEOPOROS
[8]  
Aromataris, 2020, ADELAIDE JBI
[9]  
Bowman SM, 2011, PERSPECT HLTH INF MA, V8
[10]   Updating search strategies for systematic reviews using EndNote [J].
Bramer, Wichor ;
Bain, Paul .
JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION, 2017, 105 (03) :285-289